Evaluierung neuer Tumormarker
- Wesseling S, Stephan C, Semjonow A, Lein M, Brux B, Sinha P, Loening SA, Jung K: Determination of non-alpha-1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: Analytical performance and diagnostic accuracy. Clin Chem 49: 887-94, 2003.
- Jung K, Stephan C, Semjonow A, Lein M, Schnorr D, Loening SA: Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J Urol 170: 2302-5, 2003.
- Jung K, Lein M, Stephan C, von Hösslin K, Semjonow A, Brux B, Sinha P, Loening SA, Schnorr D: Comparison of ten serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications. Int J Cancer 111: 783-9, 2004.
- Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, Stephan C, Klevecka V, Taymoorian K, Schnorr D, Recker F, Loening SA, Jung K: Multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol 170: 1175-9, 2003.
- Lein M, Semjonow A, Graefen M, Kwiatkowski M, Abramjuk C, Stephan C, Haese A, Chun F, Schnorr D, Loening SA, Jung K: A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J Urol 174: 2150-53, 2005.
- Larsson A, Ronquist G, Wülfing C, Eltze E, Bettendorf O, Carlsson L, Nilsson BO, Semjonow A: Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liability. Urol Oncol 24: 195-200, 2006.
